Comparing Three Different Anti-Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective Study.

Multiple programmed death-ligand 1 (PD-L1) immunohistochemistry assays performed using different antibodies including DAKO 22C3, DAKO 28-8, and Ventana SP142 PD-L1-predictive markers for response to various immune checkpoint inhibitors in NSCLC-have been approved in several countries. The differences in multiple PD-L1 immunohistochemistry assay results in predicting the therapeutic response to combined chemoimmunotherapy in patients with NSCLC remain unclear. In this multicenter prospective observational study, we monitored 70 patients with advanced NSCLC treated with combined chemoimmunotherapy at 10 institutions in Japan. The expression of PD-L1 in pretreatment tumors was evaluated using the 22C3, 28-8, and SP142 assays in all patients. The PD-L1 level in tumor cells determined using the 22C3 assay was the highest among the three assays performed with different antibodies. According to the 22C3 assay results, the PD-L1 tumor proportion score greater than or equal to 50% group had a significantly longer progression-free survival period than the PD-L1 tumor proportion score less than 50% group. Nevertheless, the other assays did not reveal remarkable differences in the objective response rate or progression-free survival. In our study, PD-L1 expression determined using the 22C3 assay was more correlated with the therapeutic response of patients with NSCLC treated with combined chemoimmunotherapy than that determined using the 28-8 and SP142 assays. Therefore, the 22C3 assay may be useful for clinical decision-making for patients with NSCLC treated with combined chemoimmunotherapy. Trial registration number: UMIN 000043958.

Informations de copyright

© 2024 The Authors.

Déclaration de conflit d'intérêts

Dr. Tadaaki Yamada reports receiving research grants from 10.13039/100004319Pfizer, 10.13039/501100013170Ono Pharmaceutical, 10.13039/100020707Janssen Pharmaceutical, 10.13039/100004325AstraZeneca, and Takeda Pharmaceutical; and personal fees from Eli Lilly. Dr. Takayama received grants from 10.13039/100010795Chugai Pharmaceutical and Ono Pharmaceutical; and personal fees from AstraZeneca, Chugai Pharmaceutical, Merck Sharp & Dohme, Eli Lilly, Boehringer Ingelheim, and Daiichi Sankyo. The remining authors declare no conflict of interest.